Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311140992> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W4311140992 endingPage "100270" @default.
- W4311140992 startingPage "100270" @default.
- W4311140992 abstract "Treatment [tx] options for platinum-resistant ovarian cancer [PROC] are limited [ltd]. Immune checkpoint inhibitors (ICI) have ltd activity in PROC. Clinical studies evaluating novel therapies are urgently needed. COM701, a novel, 1st in-class ICI binds to PVRIG, leading to activation of T-cells. BMS-986207 is an ICI blocker of TIGIT. We reported a partial response [PR] with COM701 monotherapy in a pt with primary peritoneal CA1. We hypothesized that in pts with PROC, blocking the DNAM axis with the triplet: COM701 + BMS-986207 + nivolumab, would demonstrate antitumor activity with a favorable safety and tolerability profile. We present preliminary results. All 20 pts enrolled received COM701 20 mg/kg + BMS-986207 480 mg + nivolumab 480 mg IV Q4W. Primary objectives [obj] were safety/tolerability; secondary obj of antitumor activity. Key inclusion criteria: Age ≥ 18 yrs, histologically confirmed advanced malignancies and exhausted all available standard tx. Key exclusion criteria: prior receipt of any inhibitor of PVRIG, TIGIT, or PD-1/PD-L1. Investigator assessed responses per RECIST v1.1, safety per CTCAE v5.0. Median [med] age 61yr, med follow-up 51 days [range 1-202], med number of prior lines of therapy - 4 [range 1-10]. Objective response rate 4/20 [20%] pts [all ongoing study tx, 3 confirmed PR], 3 PRs - serous adenoCA, 1 PR - clear cell histology. No complete responses (CR); 4pts with stable disease (SD), disease control rate [CR+PR+SD] 8/20 [40%]. Most frequent [freq] histology - serous adenoCA 10/20 [50%], clear cell 3/20 [15%]. Most freq AE G1/2 fatigue in 11 pts. A sustained immune activation induced by the tx, with a maximum 7.6-fold average increase of peripheral IFNɣ in 16pts evaluated [p<0.005]. The combination of COM701 + BMS-986207 + nivolumab has encouraging signal of antitumor activity with immune activation in pts with heavily pre-treated PROC and is well tolerated. Additional data will be presented at the conference. Data extract 08/29/2022. 1. Vaena D et al, COM701±nivolumab: Results of an ongoing P1 study of safety, tolerability & preliminary antitumor activity in pts with advanced solid malig. J Clin Onco 39, 2021 (suppl 15; abst 2504)." @default.
- W4311140992 created "2022-12-23" @default.
- W4311140992 creator A5000069330 @default.
- W4311140992 creator A5002292724 @default.
- W4311140992 creator A5006362581 @default.
- W4311140992 creator A5017109935 @default.
- W4311140992 creator A5025594305 @default.
- W4311140992 creator A5033389651 @default.
- W4311140992 creator A5037027103 @default.
- W4311140992 creator A5039531981 @default.
- W4311140992 creator A5041240405 @default.
- W4311140992 creator A5043985877 @default.
- W4311140992 creator A5050119773 @default.
- W4311140992 creator A5060086956 @default.
- W4311140992 creator A5063267546 @default.
- W4311140992 creator A5071392456 @default.
- W4311140992 creator A5081050769 @default.
- W4311140992 creator A5082776932 @default.
- W4311140992 creator A5085850419 @default.
- W4311140992 date "2022-12-01" @default.
- W4311140992 modified "2023-10-18" @default.
- W4311140992 title "158P Triple blockade of the DNAM-axis with COM701 + BMS-986207 + nivolumab demonstrates preliminary antitumor activity in patients with platinum-resistant OVCA" @default.
- W4311140992 doi "https://doi.org/10.1016/j.iotech.2022.100270" @default.
- W4311140992 hasPublicationYear "2022" @default.
- W4311140992 type Work @default.
- W4311140992 citedByCount "0" @default.
- W4311140992 crossrefType "journal-article" @default.
- W4311140992 hasAuthorship W4311140992A5000069330 @default.
- W4311140992 hasAuthorship W4311140992A5002292724 @default.
- W4311140992 hasAuthorship W4311140992A5006362581 @default.
- W4311140992 hasAuthorship W4311140992A5017109935 @default.
- W4311140992 hasAuthorship W4311140992A5025594305 @default.
- W4311140992 hasAuthorship W4311140992A5033389651 @default.
- W4311140992 hasAuthorship W4311140992A5037027103 @default.
- W4311140992 hasAuthorship W4311140992A5039531981 @default.
- W4311140992 hasAuthorship W4311140992A5041240405 @default.
- W4311140992 hasAuthorship W4311140992A5043985877 @default.
- W4311140992 hasAuthorship W4311140992A5050119773 @default.
- W4311140992 hasAuthorship W4311140992A5060086956 @default.
- W4311140992 hasAuthorship W4311140992A5063267546 @default.
- W4311140992 hasAuthorship W4311140992A5071392456 @default.
- W4311140992 hasAuthorship W4311140992A5081050769 @default.
- W4311140992 hasAuthorship W4311140992A5082776932 @default.
- W4311140992 hasAuthorship W4311140992A5085850419 @default.
- W4311140992 hasBestOaLocation W43111409921 @default.
- W4311140992 hasConcept C121608353 @default.
- W4311140992 hasConcept C126322002 @default.
- W4311140992 hasConcept C126894567 @default.
- W4311140992 hasConcept C143998085 @default.
- W4311140992 hasConcept C197934379 @default.
- W4311140992 hasConcept C2776694085 @default.
- W4311140992 hasConcept C2777701055 @default.
- W4311140992 hasConcept C2778375690 @default.
- W4311140992 hasConcept C2778822529 @default.
- W4311140992 hasConcept C2780030458 @default.
- W4311140992 hasConcept C71924100 @default.
- W4311140992 hasConcept C90924648 @default.
- W4311140992 hasConcept C98274493 @default.
- W4311140992 hasConceptScore W4311140992C121608353 @default.
- W4311140992 hasConceptScore W4311140992C126322002 @default.
- W4311140992 hasConceptScore W4311140992C126894567 @default.
- W4311140992 hasConceptScore W4311140992C143998085 @default.
- W4311140992 hasConceptScore W4311140992C197934379 @default.
- W4311140992 hasConceptScore W4311140992C2776694085 @default.
- W4311140992 hasConceptScore W4311140992C2777701055 @default.
- W4311140992 hasConceptScore W4311140992C2778375690 @default.
- W4311140992 hasConceptScore W4311140992C2778822529 @default.
- W4311140992 hasConceptScore W4311140992C2780030458 @default.
- W4311140992 hasConceptScore W4311140992C71924100 @default.
- W4311140992 hasConceptScore W4311140992C90924648 @default.
- W4311140992 hasConceptScore W4311140992C98274493 @default.
- W4311140992 hasLocation W43111409921 @default.
- W4311140992 hasOpenAccess W4311140992 @default.
- W4311140992 hasPrimaryLocation W43111409921 @default.
- W4311140992 hasRelatedWork W2087016115 @default.
- W4311140992 hasRelatedWork W2126633948 @default.
- W4311140992 hasRelatedWork W2586113026 @default.
- W4311140992 hasRelatedWork W2738397398 @default.
- W4311140992 hasRelatedWork W2891365492 @default.
- W4311140992 hasRelatedWork W2898435182 @default.
- W4311140992 hasRelatedWork W2972494744 @default.
- W4311140992 hasRelatedWork W2993816782 @default.
- W4311140992 hasRelatedWork W3028884037 @default.
- W4311140992 hasRelatedWork W3090664821 @default.
- W4311140992 hasVolume "16" @default.
- W4311140992 isParatext "false" @default.
- W4311140992 isRetracted "false" @default.
- W4311140992 workType "article" @default.